The medical data analytics platform has raised $5m from Merck Global Health Innovation Fund, adding to $23m raised last year.

Alexandria Venture Investments has helped UW's genetic sequencing technology developer TwinStand raise series A financing.

Existing investor Alexandria Venture Investments has helped genetic sequencing technology developer TwinStand increase its overall funding to $21.5m.

Every day, Global University Venturing rounds up the smaller investments from across the university innovation ecosystem in its deal net.

Galecto, based on research at Lund and Edinburgh universities, is merging with PharmAkea, with the joint entity retaining the Galecto name and leadership team.

The colectomy-focused robotic surgical device developer has now assembled $51.7m having spun out from University of Nebraska Medical Center in 2006.

Inserm Transfer Initiative featured in the first round for VectivBio, a short bowel syndrome treatment developer spun out of Therachon following the latter's acquisition by Pfizer.

Novo took part in the first round for VectivBio, a short bowel syndrome treatment developer launched out of genetic disease drug developer Therachon.

The colectomy-focused surgical device developer, which counts SinoPharm as an earlier investor, has secured series B-plus funding, in a round led by Bluestem Capital.

Galecto, whose investors include Novo, Merck Group and Bristol-Myers Squibb, is merging with Celgene-backed PharmAkea, with the joint entity retaining the Galecto name and leadership team.